Solid Biosciences Q4 net loss widens on higher R&D costs

Solid Biosciences

19/03/2026 20:34

Overview

US genetic medicine developer's Q4 net loss widened yr/yr, driven by higher R&D expenses

Outlook

Solid anticipates cash runway to extend into H1 2028 after $240 mln private placement

Result Drivers

SGT-003 COSTS - Higher R&D expenses were mainly due to increased manufacturing and clinical costs for SGT-003

PERSONNEL EXPENSES - R&D and G&A expenses rose due to higher personnel-related costs

PIPELINE ADVANCEMENT - Increased expenses also reflected progress in other pipeline programs, including SGT-601 and SGT-501

Company press release: ID:nGNX6lWz98

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$49.8 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 124.7% above its March 18 closing price of $7.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)